UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder
This review will examine the preclinical and clinical evidence that psychoplastogens, such as ibogaine, ketamine, and classic psychedelics, may offer a unique, holistic alternative for the treatment of OUD.
Associations between individual hallucinogens and hallucinogen misuse among U.S. Adults who recently initiated hallucinogen use
Hallucinogen dependence and abuse are DSM-IV diagnoses that are associated with significant morbidity, yet the specific hallucinogens that are most strongly linked to dependence and abuse are understudied.
Changed substance use after psychedelic experiences among individuals in Canada
Participants reported substantial changes, with 43.8% (n = 651/1488) decreasing or ceasing alcohol use, 42.5% (n = 272/640) ceasing or decreasing antidepressant use, and 42.4% (n = 200/471) decreasing or ceasing cocaine use.
Perspectives on the therapeutic potential of MDMA: A nation-wide exploratory survey among substance users
Overall, a majority of individuals reported a willingness to try MDMA-assisted therapy if it were determined to be an appropriate treatment for them (58.8%).
IUPHAR – invited review - Ibogaine – A legacy within the current renaissance of psychedelic therapy
Ibogaine is a powerful psychoactive substance that not only alters perception, mood and affect, but also stops addictive behaviors.
Therapeutic effect of psilocybin in addiction: A systematic review
Larger RCTs in patients with SUDs need to evaluate whether psilocybin-assisted therapy is effective in patients with SUD.